Apotex sues FDA to block Teva's H-W exclusivity for Cozaar/Hyzaar: Apotex is saying that the patent expired because Merck? didn't pay fees to the USPTO therefore, Teva should not have exclusivity. I think they can only delay Teva from launching with exclusivity.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.